Pharmacologic treatment of body dysmorphic disorder

Sallie Jo Hadley, Suah Kim, Lauren Priday, Eric Hollander

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Compared to other psychiatric disorders, pharmacologic treatment research for body dysmorphic disorder (BDD) is in the early stages. Consequently, there are no medications with a Food and Drug Administration indication for the treatment of BDD. Evidence from case reports, retrospective reviews, open-label studies, and a growing number of controlled trials have consistently demonstrated seoronin reuptake inhibitor (SRI) superiority over other psychotropic medications for the treatment of BDD. Thus, SRIs are usually the first-line choice of pharmacologic treatment for BDD. In general, higher doses than used for treating other disorders are needed to treat BDD. Also, a longer time interval of treatment may be required before a clinical response to the SRI is evident. In fact, some BDD experts suggest that up to 12 weeks of SRI treatment with at least 2-4 weeks of the total treatment at the highest recommended dose (and tolerated by the patient) should be given before determining that an SRI is ineffective. Use of SRIs for treatment of BDD along with comorbid mood, anxiety, eating, substance abuse, or impulse-control disorders can be challenging. Choice and dose of a particular SRI may be affected by the other medications used to target comorbidity. If BDD symptoms remain refractory to SRI pharmacotherapy, reported strategies for achieving symptom reduction include augmenting the SRI with another psychotropic medication (or cognitive-behavioral therapy), or switching to a different SRI or psychotropic medication.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalPrimary Psychiatry
Volume13
Issue number7
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Body Dysmorphic Disorders
Therapeutics
Disruptive, Impulse Control, and Conduct Disorders
Cognitive Therapy
United States Food and Drug Administration
Substance-Related Disorders
Psychiatry
Comorbidity
Anxiety
Eating
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Genetics

Cite this

Hadley, S. J., Kim, S., Priday, L., & Hollander, E. (2006). Pharmacologic treatment of body dysmorphic disorder. Primary Psychiatry, 13(7), 61-69.

Pharmacologic treatment of body dysmorphic disorder. / Hadley, Sallie Jo; Kim, Suah; Priday, Lauren; Hollander, Eric.

In: Primary Psychiatry, Vol. 13, No. 7, 07.2006, p. 61-69.

Research output: Contribution to journalArticle

Hadley, SJ, Kim, S, Priday, L & Hollander, E 2006, 'Pharmacologic treatment of body dysmorphic disorder', Primary Psychiatry, vol. 13, no. 7, pp. 61-69.
Hadley, Sallie Jo ; Kim, Suah ; Priday, Lauren ; Hollander, Eric. / Pharmacologic treatment of body dysmorphic disorder. In: Primary Psychiatry. 2006 ; Vol. 13, No. 7. pp. 61-69.
@article{5b45867b1b3f4d68a3c1b9765db028b9,
title = "Pharmacologic treatment of body dysmorphic disorder",
abstract = "Compared to other psychiatric disorders, pharmacologic treatment research for body dysmorphic disorder (BDD) is in the early stages. Consequently, there are no medications with a Food and Drug Administration indication for the treatment of BDD. Evidence from case reports, retrospective reviews, open-label studies, and a growing number of controlled trials have consistently demonstrated seoronin reuptake inhibitor (SRI) superiority over other psychotropic medications for the treatment of BDD. Thus, SRIs are usually the first-line choice of pharmacologic treatment for BDD. In general, higher doses than used for treating other disorders are needed to treat BDD. Also, a longer time interval of treatment may be required before a clinical response to the SRI is evident. In fact, some BDD experts suggest that up to 12 weeks of SRI treatment with at least 2-4 weeks of the total treatment at the highest recommended dose (and tolerated by the patient) should be given before determining that an SRI is ineffective. Use of SRIs for treatment of BDD along with comorbid mood, anxiety, eating, substance abuse, or impulse-control disorders can be challenging. Choice and dose of a particular SRI may be affected by the other medications used to target comorbidity. If BDD symptoms remain refractory to SRI pharmacotherapy, reported strategies for achieving symptom reduction include augmenting the SRI with another psychotropic medication (or cognitive-behavioral therapy), or switching to a different SRI or psychotropic medication.",
author = "Hadley, {Sallie Jo} and Suah Kim and Lauren Priday and Eric Hollander",
year = "2006",
month = "7",
language = "English (US)",
volume = "13",
pages = "61--69",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "7",

}

TY - JOUR

T1 - Pharmacologic treatment of body dysmorphic disorder

AU - Hadley, Sallie Jo

AU - Kim, Suah

AU - Priday, Lauren

AU - Hollander, Eric

PY - 2006/7

Y1 - 2006/7

N2 - Compared to other psychiatric disorders, pharmacologic treatment research for body dysmorphic disorder (BDD) is in the early stages. Consequently, there are no medications with a Food and Drug Administration indication for the treatment of BDD. Evidence from case reports, retrospective reviews, open-label studies, and a growing number of controlled trials have consistently demonstrated seoronin reuptake inhibitor (SRI) superiority over other psychotropic medications for the treatment of BDD. Thus, SRIs are usually the first-line choice of pharmacologic treatment for BDD. In general, higher doses than used for treating other disorders are needed to treat BDD. Also, a longer time interval of treatment may be required before a clinical response to the SRI is evident. In fact, some BDD experts suggest that up to 12 weeks of SRI treatment with at least 2-4 weeks of the total treatment at the highest recommended dose (and tolerated by the patient) should be given before determining that an SRI is ineffective. Use of SRIs for treatment of BDD along with comorbid mood, anxiety, eating, substance abuse, or impulse-control disorders can be challenging. Choice and dose of a particular SRI may be affected by the other medications used to target comorbidity. If BDD symptoms remain refractory to SRI pharmacotherapy, reported strategies for achieving symptom reduction include augmenting the SRI with another psychotropic medication (or cognitive-behavioral therapy), or switching to a different SRI or psychotropic medication.

AB - Compared to other psychiatric disorders, pharmacologic treatment research for body dysmorphic disorder (BDD) is in the early stages. Consequently, there are no medications with a Food and Drug Administration indication for the treatment of BDD. Evidence from case reports, retrospective reviews, open-label studies, and a growing number of controlled trials have consistently demonstrated seoronin reuptake inhibitor (SRI) superiority over other psychotropic medications for the treatment of BDD. Thus, SRIs are usually the first-line choice of pharmacologic treatment for BDD. In general, higher doses than used for treating other disorders are needed to treat BDD. Also, a longer time interval of treatment may be required before a clinical response to the SRI is evident. In fact, some BDD experts suggest that up to 12 weeks of SRI treatment with at least 2-4 weeks of the total treatment at the highest recommended dose (and tolerated by the patient) should be given before determining that an SRI is ineffective. Use of SRIs for treatment of BDD along with comorbid mood, anxiety, eating, substance abuse, or impulse-control disorders can be challenging. Choice and dose of a particular SRI may be affected by the other medications used to target comorbidity. If BDD symptoms remain refractory to SRI pharmacotherapy, reported strategies for achieving symptom reduction include augmenting the SRI with another psychotropic medication (or cognitive-behavioral therapy), or switching to a different SRI or psychotropic medication.

UR - http://www.scopus.com/inward/record.url?scp=33746238167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746238167&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 61

EP - 69

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 7

ER -